95 related articles for article (PubMed ID: 20734138)
1. The pharmaceutical care of patients with type 2 diabetes mellitus.
Borges AP; Guidoni CM; Ferreira LD; de Freitas O; Pereira LR
Pharm World Sci; 2010 Dec; 32(6):730-6. PubMed ID: 20734138
[TBL] [Abstract][Full Text] [Related]
2. Improvement of diabetes indices of care by a short pharmaceutical care program.
Turnacilar M; Sancar M; Apikoglu-Rabus S; Hursitoglu M; Izzettin FV
Pharm World Sci; 2009 Dec; 31(6):689-95. PubMed ID: 19777365
[TBL] [Abstract][Full Text] [Related]
3. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil.
Correr CJ; Melchiors AC; Fernandez-Llimos F; Pontarolo R
Int J Clin Pharm; 2011 Apr; 33(2):273-80. PubMed ID: 21394570
[TBL] [Abstract][Full Text] [Related]
4. Improved Glycemic Control With Minimal Change in Medication Regimen Complexity in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic.
Morello CM; Rotunno T; Khoan J; Hirsch JD
Ann Pharmacother; 2018 Nov; 52(11):1091-1097. PubMed ID: 29775079
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update.
; Lipscombe L; Butalia S; Dasgupta K; Eurich DT; MacCallum L; Shah BR; Simpson S; Senior PA
Can J Diabetes; 2020 Oct; 44(7):575-591. PubMed ID: 32972640
[No Abstract] [Full Text] [Related]
7. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - The User's Guide.
; Senior PA; Houlden RL; Kim J; Mackay D; Nagpal S; Rabi D; Sherifali D; Bajaj HS
Can J Diabetes; 2020 Oct; 44(7):592-596. PubMed ID: 32972641
[No Abstract] [Full Text] [Related]
8. Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial.
Mourão AO; Ferreira WR; Martins MA; Reis AM; Carrillo MR; Guimarães AG; Ev LS
Int J Clin Pharm; 2013 Feb; 35(1):79-86. PubMed ID: 23161124
[TBL] [Abstract][Full Text] [Related]
9. Medication use and disease management of type 2 diabetes in Belgium.
Mehuys E; De Bolle L; Van Bortel L; Annemans L; Van Tongelen I; Remon JP; Giri M
Pharm World Sci; 2008 Jan; 30(1):51-6. PubMed ID: 17588213
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical care model for patients with type 2 diabetes: integration of the community pharmacist into the diabetes team--a pilot study.
Wermeille J; Bennie M; Brown I; McKnight J
Pharm World Sci; 2004 Feb; 26(1):18-25. PubMed ID: 15018255
[TBL] [Abstract][Full Text] [Related]
11. The influence of pharmacist-led adherence support on glycaemic control in people with type 2 diabetes.
Kharjul M; Braund R; Green J
Int J Clin Pharm; 2018 Apr; 40(2):354-359. PubMed ID: 29468528
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of a pharmacist-managed glucose collaborative practice agreement.
Pugazhenthi V; Dick TB; Call M
Am J Health Syst Pharm; 2016 Dec; 73(23 Supplement 6):S148-S154. PubMed ID: 27864238
[TBL] [Abstract][Full Text] [Related]
13. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
Vinik A
Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
[TBL] [Abstract][Full Text] [Related]
14. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic.
Irons BK; Lenz RJ; Anderson SL; Wharton BL; Habeger B; Anderson HG
Pharmacotherapy; 2002 Oct; 22(10):1294-300. PubMed ID: 12389879
[TBL] [Abstract][Full Text] [Related]
15. Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care.
Gnanasan S; Ting KN; Wong KT; Mohd Ali S; Muttalif AR; Anderson C
Int J Clin Pharm; 2011 Feb; 33(1):44-52. PubMed ID: 21365392
[TBL] [Abstract][Full Text] [Related]
16. Effects of pharmacist prescribing on patient outcomes in the hospital setting: a systematic review.
Poh EW; McArthur A; Stephenson M; Roughead EE
JBI Database System Rev Implement Rep; 2018 Sep; 16(9):1823-1873. PubMed ID: 30204671
[TBL] [Abstract][Full Text] [Related]
17. Treatment choices for the glycaemic management of patients with type 2 diabetes and chronic kidney disease: Analysis of the SAIL patient linked dataset.
Min T; Davies GI; Rice S; Chess J; Stephens JW
Diabetes Metab Syndr; 2018; 12(2):123-127. PubMed ID: 29239764
[TBL] [Abstract][Full Text] [Related]
18. Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program.
DeName B; Divine H; Nicholas A; Steinke DT; Johnson CL
J Am Pharm Assoc (2003); 2008; 48(6):731-6. PubMed ID: 19019801
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control.
Yamanouchi T; Ogata N; Tagaya T; Kawasaki T; Sekino N; Funato H; Akaoka L; Miyashita H
Lancet; 1996 Jun; 347(9014):1514-8. PubMed ID: 8684103
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and sustainability of a structured group-based educational program (MEDIHEALTH) in improving medication adherence among Malay patients with underlying type 2 diabetes mellitus in Sarawak State of Malaysia: study protocol of a randomized controlled trial.
Ting CY; Ahmad Zaidi Adruce S; Hassali MA; Ting H; Lim CJ; Ting RS; Abd Jabar AHA; Osman NA; Shuib IS; Loo SC; Sim ST; Lim SE; Morisky DE
Trials; 2018 Jun; 19(1):310. PubMed ID: 29871651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
